CASI Pharmaceuticals Operating Income

CASI Pharmaceuticals's operating income stands at $-45M as of September 2025. That compares with $-37M in the prior-year period — down 20.5% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

CASI Pharmaceuticals reported $-45M in operating income versus $-37M a year earlier — a 20.5% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $-37M in the prior-year period — down 20.5% year over year. Sustained growth in operating income can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how CASI Pharmaceuticals's operating income evolved across reporting periods, while the comparison chart places CASI next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, operating income is commonly used to spot outliers. CASI Pharmaceuticals's reading of $-45M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.